DOI: 10.3390/healthcare11152210 ISSN: 2227-9032

Frequency of Autoantibodies on Non-Hodgkin Lymphoma

Sonia Guadalupe Barreno-Rocha, Sandra Guzmán-Silahua, Ernesto Germán Cardona-Muñoz, Maria Guadalupe Zavala-Cerna, David Eduardo Muñoz Gaytan, Carlos Riebeling-Navarro, Benjamín Rubio-Jurado, Arnulfo Hernán Nava-Zavala
  • Health Information Management
  • Health Informatics
  • Health Policy
  • Leadership and Management

(1) Background: Non-Hodgkin Lymphoma is a neoplasm that can significantly compromise the immune system, but timely assessment can change the patient outcome. In cancer, the activation of the immune system could lead to the secretion of autoantibodies. (2) Methods: A retrospective cohort study was performed from 2017 to 2019 in patients with Non-Hodgkin Lymphoma diagnosed with a biopsy. (3) Results: We included 39 patients who were newly diagnosed, untreated, and without any autoimmune disease previously reported. Thirty patients had the presence of autoantibodies (antiphospholipid antibodies, anti-cytoplasmic neutrophils antibodies, antinuclear antibodies), and nine were without autoantibodies. There were no statistical differences among groups regarding clinical, demographic, staging, and prognosis characteristics. Also, there were no differences in the outcomes of the patients after finishing chemotherapy and one year after initiating treatment. (4) Conclusions: Further investigations must be conducted regarding an extended panel of autoantibodies because the panel of autoantibodies in this study did not show a relationship between the presence and the clinical outcome of the patients.

More from our Archive